Barrett’s Research
Yucca Health$129-1.5%SkinnyRx$1990.0%ShedRx$195-1.0%MEDVi$1790.0%Embody$99+1.0%Bodybuilding Health+$139-2.1%Yucca Health$129-1.5%SkinnyRx$1990.0%ShedRx$195-1.0%MEDVi$1790.0%Embody$99+1.0%Bodybuilding Health+$139-2.1%
Litigation tracker

Where the GLP-1 Lawsuits Stand in 2026

If headlines about Ozempic lawsuits have left you uneasy, let's take a calm look together. The cases now seek more than $2 billion in combined damages, with people alleging Novo Nordisk didn't warn clearly enough about slowed stomach emptying (gastroparesis), gallbladder removal and vision loss. We'll walk through where each major case stands — and, just as importantly, what it does and doesn't mean if you're taking one of these medications.

By Rihab Yassin, Ph.D., Health Technology Researcher & Publisher. Published January 10, 2026.

The landscape

The numbers, at a glance

8
Active cases
1
Settled
100s
Individual plaintiffs
$2B+
Potential damages

Seed data — verify before relying on it.

Case by case

Where each one stands today

Active and settled cases, newest first. We keep the language factual here so you can draw your own conclusions.

ACTIVEApril 2026

NAION Vision Loss Lawsuits Centralized in Federal MDL

Defendants: Novo Nordisk, Eli Lilly

Drugs: Semaglutide (Ozempic, Wegovy), Tirzepatide (Mounjaro, Zepbound)

Allegations: Plaintiffs allege the drugs caused non-arteritic anterior ischemic optic neuropathy (NAION) — sudden vision loss — and that manufacturers knew the risk from trial data but failed to warn adequately.

Key details: A 2024 Harvard study found semaglutide users had a significantly elevated NAION risk. The FDA expanded its investigation in early 2026. Plaintiffs report partial or complete vision loss in one or both eyes.

Next steps

An MDL consolidation hearing is scheduled. Bellwether trial selection is expected in late 2026.

ACTIVEMarch 2026

Ozempic Gallbladder Injury Lawsuits — Cholecystectomy Claims

Defendants: Novo Nordisk

Drugs: Semaglutide (Ozempic, Wegovy)

Allegations: Suits allege semaglutide caused acute gallbladder disease, gallstones, and cholecystitis requiring emergency removal, and that Novo downplayed the risk despite trial data.

Key details: FDA adverse-event reports show thousands of gallbladder complaints. A 2022 study found higher gallbladder event rates in GLP-1 users versus placebo; many plaintiffs had no prior gallbladder issues.

Next steps

Cases are being consolidated with the gastroparesis MDL. Bellwether selection is anticipated in late 2026.

ACTIVEFebruary 2026

Gastroparesis / Stomach Paralysis Mass Tort Litigation

Defendants: Novo Nordisk, Eli Lilly

Drugs: Semaglutide, Tirzepatide, Liraglutide

Allegations: Hundreds allege the drugs caused severe gastroparesis, cyclic vomiting syndrome, and intestinal obstruction, with some symptoms persisting months or years after stopping.

Key details: The litigation argues manufacturers failed to adequately warn about the severity and duration of GI effects. Several cases involve hospitalization for bowel obstructions.

Next steps

Discovery is ongoing; expert witness reports are due mid-2026. Settlement talks have not begun.

ACTIVEJanuary 2026

Novo Nordisk Class Action — Pricing & Supply Manipulation

Defendants: Novo Nordisk A/S

Drugs: Ozempic, Wegovy

Allegations: Plaintiffs allege Novo artificially maintained the semaglutide shortage to keep prices high and block compounding competition, while manipulating FDA supply data.

Key details: The class includes patients who paid inflated prices and compounding pharmacies. The suit seeks damages for overcharges and injunctive relief.

Next steps

A class certification hearing is scheduled for Q2 2026. Novo has filed a motion to dismiss.

ACTIVEJanuary 2026

Novo Nordisk Securities Class Action — Failure to Disclose Safety Risks

Defendants: Novo Nordisk A/S

Drugs: Ozempic, Wegovy

Allegations: Shareholders allege Novo failed to disclose known safety risks (vision loss, severe gastroparesis), inflating the stock price that later fell when the signals became public.

Key details: The complaint cites internal documents suggesting awareness of elevated NAION risk before public disclosure and alleges risks were downplayed to investors.

Next steps

A lead plaintiff was appointed and an amended complaint filed. A motion to dismiss is pending.

SETTLEDNovember 2025

FTC Settlement — NextMed Pays $150K for Deceptive GLP-1 Claims

Defendants: NextMed (telehealth provider)

Drugs: Semaglutide, Tirzepatide

Allegations: The FTC alleged deceptive advertising: guaranteed weight-loss claims, misleading before/after photos, unsubstantiated testimonials, and undisclosed endorser connections.

Key details: The provider agreed to pay $150,000 and accept a permanent injunction against future deceptive claims.

Next steps

The settlement is finalized. NextMed is subject to compliance monitoring for five years.

ACTIVEDecember 2025

Compounding Pharmacy Fraud — Multi-State Criminal Investigation

Defendants: Multiple compounding pharmacies (names sealed)

Drugs: Compounded Semaglutide, Compounded Tirzepatide

Allegations: Federal prosecutors are pursuing wire fraud, introduction of adulterated drugs, and conspiracy to defraud patients.

Key details: Investigators uncovered vials labeled as semaglutide with little or no active ingredient, undisclosed substances, and forged certificates of analysis from unlicensed pharmacies.

Next steps

Grand jury proceedings are underway in three federal districts. Indictments are expected in Q2 2026.

ACTIVEOctober 2025

Pancreatitis Wrongful Death Lawsuits

Defendants: Novo Nordisk, Eli Lilly

Drugs: Semaglutide, Tirzepatide

Allegations: Families of patients who died from acute pancreatitis allegedly caused by GLP-1s claim the manufacturers gave inadequate severity warnings.

Key details: The suits cite patients who developed necrotizing pancreatitis within weeks of starting, leading to multi-organ failure and death.

Next steps

Individual cases are proceeding in state courts. No consolidation has been sought at this time.

ACTIVESeptember 2025

Eli Lilly Patent Enforcement — Compounding Pharmacy Injunctions

Defendants: Multiple compounding pharmacies

Drugs: Compounded Tirzepatide

Allegations: Eli Lilly brought patent-infringement suits against compounders making tirzepatide copies, arguing tirzepatide was never in shortage so there was no legal basis to compound it.

Key details: Lilly obtained temporary restraining orders against several pharmacies and is seeking permanent injunctions, citing both safety risk and IP infringement.

Next steps

Preliminary injunction hearings are ongoing. Several pharmacies stopped tirzepatide compounding voluntarily.

The math behind the headline

Where does the $2 billion figure come from?

It's not one giant payout — it's the combined total of thousands of individual claims being pulled together in a federal MDL, spread across three main types of injury.

Gastroparesis

The biggest group of claims — severe nausea, vomiting and hospital stays that can drag on for months or even years.

Gallbladder injuries

Gallstones and emergency removals, backed by thousands of adverse-event reports to the FDA.

NAION vision loss

Sudden loss of vision, supported by the 2024 Harvard study linking semaglutide to a higher NAION risk.

For perspective, estimated settlements run from roughly $100,000 to $500,000+ per person depending on how serious the injury is. As of April 2026 there's no class-action settlement yet, and the first bellwether trials are expected in late 2026 or early 2027 — so this is still very much in motion.

The part that matters most

So what does all this mean for you?

Lawsuit news can feel scary, but it doesn't have to change your day. Here's how to think about it calmly.

1

These medications are still FDA-approved

Here's the part that reassures most people: the suits argue the warnings weren't strong enough, not that the drugs should be pulled. Millions keep using them safely.

2

Talk through your own risk factors

It's worth a quick conversation with your doctor about any history of pancreatitis, vision problems or severe stomach issues — just so you're both on the same page.

3

Keep simple notes if something goes wrong

Jot down dates, symptoms and visits. It helps your care first and foremost, and it would matter for any legal claim down the line.

4

Be choosy about compounded products

Sticking to FDA-approved or 503B-facility products takes a lot of the added uncertainty off the table.

5

Talk to a lawyer if you were seriously harmed

If you've had a serious adverse effect, a pharmaceutical litigation attorney can tell you whether you have a claim. There's no harm in asking.

Legal disclaimer

We share this for information only — it isn't legal advice. We pull case details from public court records, FDA enforcement actions and news reports, and statuses change often, so please treat this as a starting point rather than the final word. If you've been seriously affected, a qualified attorney can give you guidance specific to your situation.

Stay in the loop, stay reassured

The best antidote to anxious headlines is good information. We'll keep both of these updated for you.

See the FDA alertsCheck a provider

Related Resources

🚨

FDA Alerts, Made Readable

Every warning letter and enforcement action, in plain English.

🔍

Is My Provider for Real?

A quick red-flag checklist to confirm your provider is legitimate.

🩺

Your Side Effects Companion

Every side effect explained kindly, with what helps.

⚖️

Compounded vs. Brand-Name

The honest differences in safety, cost and legality.

🏆

Programs We'd Recommend

The telehealth providers we'd point a friend toward.

2-minute match quiz

Not sure which program is the right fit?

Answer six quick questions and we'll point you to the programs that suit your budget, your insurance, and how you want to be cared for.

Find your match See our top programs